| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Email: |
chemcell@hotmail.com |
| Products Intro: |
Product Name:AZD4604
CAS:2241039-81-4
Purity:98% Package:5mg；10mg；20mg；50mg；100mg；250mg；500mg；1g；5g；10g；25g；100g
|
JAK1-IN-7 manufacturers
- Londamocitinib
-
- $189.00 / 1mg
-
2025-07-29
- CAS:2241039-81-4
- Min. Order:
- Purity: 99.56%
- Supply Ability: 10g
- Londamocitinib
-
- $189.00 / 1mg
-
2025-07-14
- CAS:2241039-81-4
- Min. Order:
- Purity: 99.56%
- Supply Ability: 10g
|
| | JAK1-IN-7 Basic information |
| Product Name: | JAK1-IN-7 | | Synonyms: | JAK1-IN-7;AZD4604;JAK1IN7,JAK-1-IN-7,JAK1 IN 7;1-Piperazineacetamide, N-[3-[5-fluoro-2-[[2-fluoro-3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]-1H-indol-7-yl]-α-(methoxymethyl)-4-methyl-, (αR)-;AZD4604，
JAK1-IN-7;Londamocitinib/AZD4604/JAK1-IN-7;Londamocitinib;(R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide | | CAS: | 2241039-81-4 | | MF: | C28H31F2N7O4S | | MW: | 599.66 | | EINECS: | | | Product Categories: | | | Mol File: | 2241039-81-4.mol |  |
| | JAK1-IN-7 Chemical Properties |
| density | 1.411±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 13.90±0.30(Predicted) | | color | White to off-white |
| | JAK1-IN-7 Usage And Synthesis |
| Uses | Londamocitinib (AZD4604) is a potent and selective JAK1 inhibitor with IC50 at 0.54 nM. Londamocitinib has anti-inflammatory activity[1][2][3]. | | in vivo | Londamocitinib (1 mg/kg, intravenous injection, single dose) can reduce the phosphorylation of STAT3 and STAT5 in the lung of obumin-induced asthmatic rats, inhibit pulmonary eosinophilia, and reduce advanced asthma response in the same model[3].
| Animal Model: | OVA-Induced Rat Model of Asthma[3] | | Dosage: | 1 mg/kg | | Administration: | i.v. | | Result: | Reduced the proportion of phosphorylated STAT3-positive cell nuclei. |
| | IC 50 | JAK1: 0.54 nM (IC50) | | References | [1] NILSSON, Karl, Magnus, et al. Jak1 selective inhibitors. WO2018134213A1.
[2] Nilsson M, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. J Med Chem. 2023 Oct 12;66(19):13400-13415. DOI:10.1021/acs.jmedchem.3c00554
[3] Nilsson M, et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31;16:2901-2917. DOI:10.2147/DDDT.S354291 |
| | JAK1-IN-7 Preparation Products And Raw materials |
|